/PRNewswire/ Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the RenaCARE (Renasight Clinical Application, Review and.
/PRNewswire/ Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the RenaCARE (Renasight Clinical Application, Review and.
/PRNewswire/ Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced the results of a large, real-world study1 demonstrating a high.
Multi-Site Clinical Validation of Prospera Heart Test Demonstrates Outstanding Performance in Assessing Heart Transplant Rejection streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that its clinical validation study1 on its donor-derived.